Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
June 11, 2019
Primary Completion Date
December 30, 2019
Study Completion Date
December 30, 2019
Conditions
Undefined
Interventions
DRUG
MyMD1
Isomyosamine 5mg capsules
DRUG
Placebo
Placebo
Trial Locations (1)
33409
Palm Beach CRO, LLC, West Palm Beach
All Listed Sponsors
lead
TNF Pharmaceuticals, Inc.
INDUSTRY
NCT04349761 - Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects | Biotech Hunter | Biotech Hunter